Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
暂无分享,去创建一个
Daniel Bloomfield | J. Mckenney | R. Pasternak | D. Tribble | James M. McKenney | D. Bloomfield | Yale Mitchel | T. Littlejohn | Gary L. Carlson | Aditi Sapre | Diane Tribble | Thomas W. Littlejohn | Christine McCrary Sisk | Richard C. Pasternak | Y. Mitchel | A. Sapre | C. Sisk | G. Carlson
[1] J. Stockman,et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial , 2009 .
[2] J. Ehrhart,et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone , 2008, British journal of pharmacology.
[3] D. Grobbee,et al. Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia , 2007 .
[4] H. Mabuchi,et al. Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. , 1985, Atherosclerosis.
[5] K. Wakitani,et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits , 2000, Nature.
[6] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[7] M. Caulfield,et al. Effects of torcetrapib in patients at high risk for coronary events , 2008 .
[8] J. Mckenney,et al. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. , 2006, Journal of the American College of Cardiology.
[9] M. Kamada,et al. Effect of Antisense Oligonucleotides against Cholesteryl Ester Transfer Protein on the Development of Atherosclerosis in Cholesterol-fed Rabbits* , 1998, The Journal of Biological Chemistry.
[10] Diederick E Grobbee,et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial , 2007, The Lancet.
[11] M. Pfeffer,et al. C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.
[12] F. Zimetti,et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits Published, JLR Papers in Press, February 26, 2007. , 2007, Journal of Lipid Research.
[13] J. Danesh,et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. , 2008, JAMA.
[14] J. Stamler. Clofibrate and niacin in coronary heart disease. , 1975, JAMA.
[15] John A Wagner,et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies , 2007, The Lancet.
[16] J. Stamler,et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.
[17] A. Zwinderman,et al. Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study , 2002, Circulation.
[18] D. Cutler,et al. Effect of Torcetrapib on the Progression of Coronary Atherosclerosis , 2007 .
[19] A. Tall,et al. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. , 2006, The Journal of clinical investigation.
[20] A. Tall. Plasma cholesteryl ester transfer protein. , 1993, Journal of lipid research.
[21] J. Vander. C-Reactive Protein Levels and Outcomes After Statin Therapy , 2006 .
[22] J. Mckenney,et al. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. , 2006, Journal of the American College of Cardiology.
[23] A. Callow,et al. Vaccine-Induced Antibodies Inhibit CETP Activity In Vivo and Reduce Aortic Lesions in a Rabbit Model of Atherosclerosis , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[24] D. Rader,et al. Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[25] J. Danesh,et al. Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies , 2000, Circulation.
[26] N Rifai,et al. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. , 1999, Clinical chemistry.
[27] H. Drexel,et al. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. , 2004 .